Trial Profile
Phase 1 study to evaluate the safety, pharmacokinetic and hormone-release profile of TAK-448 when administered as single and multiple dose SC bolus or infusions in prostate cancer patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2015
Price :
$35
*
At a glance
- Drugs MVT 602 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- 20 Nov 2015 New trial record